Link to this page
National Cancer Institute Thesaurus
| Preferred Name | Daclizumab | |
| Synonyms |
Anti-Tac Monoclonal Antibody Monoclonal Antibody Anti-Tac Anti-Tac Humanized Monoclonal Antibody Humanized Anti-Tac Monoclonal Antibody Anti-Tac DACLIZUMAB Dacliximab Daclizumab Zenapax daclizumab |
|
| Definitions |
A recombinant monoclonal antibody interleukin-2 receptor antagonist. Daclizumab binds specifically to the alpha subunit of the human interleukin-2 (IL-2) receptor expressed on the surface of activated lymphocytes in vivo, thereby inhibiting IL-2 binding and IL-2-mediated lymphocyte activation, a critical cellular immune response pathway. |
|
| ID |
http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C1569 |
|
| Accepted_Therapeutic_Use_For |
Kidney transplant rejection, prevention
|
|
| ALT_DEFINITION |
A monoclonal antibody that is being studied in the treatment of adult T-cell leukemia and in the treatment of cytopenia (low blood cell count).
|
|
| CAS_Registry |
152923-56-3
|
|
| code |
C1569
|
|
| Concept_In_Subset |
http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C176424 http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157711 http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157712 http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116978 http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116977 http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128784 |
|
| Contributing_Source |
CTRP FDA GDC
|
|
| DEFINITION |
A recombinant monoclonal antibody interleukin-2 receptor antagonist. Daclizumab binds specifically to the alpha subunit of the human interleukin-2 (IL-2) receptor expressed on the surface of activated lymphocytes in vivo, thereby inhibiting IL-2 binding and IL-2-mediated lymphocyte activation, a critical cellular immune response pathway.
|
|
| Display_Name |
Daclizumab
|
|
| FDA_UNII_Code |
CUJ2MVI71Y
|
|
| FULL_SYN |
Anti-Tac Monoclonal Antibody Monoclonal Antibody Anti-Tac Anti-Tac Humanized Monoclonal Antibody Humanized Anti-Tac Monoclonal Antibody Anti-Tac DACLIZUMAB Dacliximab Daclizumab Zenapax daclizumab
|
|
| Has_Target | ||
| Is_Value_For_GDC_Property | ||
| label |
Daclizumab
|
|
| Legacy Concept Name |
Daclizumab
|
|
| Maps_To |
Daclizumab
|
|
| NCI_Drug_Dictionary_ID |
42006
|
|
| NSC Number |
725173
|
|
| PDQ_Closed_Trial_Search_ID |
42006
|
|
| PDQ_Open_Trial_Search_ID |
42006
|
|
| Preferred_Name |
Daclizumab
|
|
| prefixIRI |
Thesaurus:C1569
|
|
| Semantic_Type |
Amino Acid, Peptide, or Protein Pharmacologic Substance Immunologic Factor
|
|
| UMLS_CUI |
C0663182
|
|
| subClassOf |
| Delete | Subject | Author | Type | Created |
|---|---|---|---|---|
| No notes to display |